Page 90 - Genentech News Today

Roche is paying $50 million up front to begin a drug R&D alliance with Monte Rosa Therapeutics, a biotech whose molecular glue technology could address targets previously deemed undruggable. It’s Roche’s second such deal in the past month.

Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a bi-specific antibody New data from BioNTech’s...

MAINZ, Germany, October 16, 2023 -- On October 13, 2023, Pfizer Inc. , a collaboration partner of BioNTech SE , announced a non-cash charge for inventory write-offs and other charges related to...

Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a...

MAINZ, Germany, October 16, 2023 -- On October 13, 2023, Pfizer Inc. , a collaboration partner of BioNTech SE , announced a non-cash charge for inventory write-offs and other charges related to...

Linking mass spectroscopy with cryo-electron microscopy could transform understanding of complex protein structures — if scientists can show that samples remain intact when they hit their target. Linking mass spectroscopy with cryo-electron microscopy could transform understanding of complex protein structures — if scientists can show that samples remain intact when they hit their target.

Florida Cancer Specialists & Research Institute, LLC Director of Drug Development Manish Patel, MD is the co-author for two manuscripts published in the New England Journal of Medicine within two months.

The pharmaceutical industry’s best and brightest were recognized on October 15 at ISPE Annual Meeting & Expo in Las Vegas.

The field of protein degraders is at an inflection point as more degraders enter the clinical space. Evaluating the patent filing activity will play a critical role in the ability to managing opportunities for licensing and partnerships.

This study examines the association of the receipt of wild-type BNT162b2 vaccine with medically attended COVID-19 outcomes among children younger than 5 years i